TAK-063 Size:Solid 10 mg ME0328 enhances CRISPR-Cas9-mediated HER2 mutation

ME0328 enhances CRISPR-Cas9-mediated HER2 mutation frequency

a new anti-cancer drug candidate

The visualized decrease in megalin protein expression is confirmed by densitometry analyses

CAS Number: 2358775-70-7

TAK-063 Size:Solid 10 mg ME0328 enhances CRISPR-Cas9-mediated HER2 mutationTAK 063, also known as Balipodect., is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK 063 is currently being evaluated in clinical trials for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is a cAMP cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. TAK 063 represents a promising drug for the treatment of schizophrenia with potential for superior safety